Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion type Assertion NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_head.
- NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_provenance.
- NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion evidence source_evidence_literature NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_provenance.
- NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion SIO_000772 22210719 NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_provenance.
- NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion wasDerivedFrom befree-20150227 NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_provenance.
- NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion wasGeneratedBy ECO_0000203 NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_provenance.